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Abstract Over the last 40 years International Orthopaedics
has published a series of articles on bone morphogenetic pro-
teins (BMPs) covering topics from basic research to clinical
applications. This includes also work submitted from the
Laboratory for Mineralized Tissues of the School of
Medicine University of Zagreb. Accordingly, we felt obliged
to give a short summary of Dr. Urist’s life and work as our
gratitude to his discovery that demineralized bone matrix
(DBM) activity induces bone when implanted ectopically into
the muscle or under the skin due to bone inducing proteins,
named BMPs.
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Dr. Marshall R. Urist was born in Chicago on June 11, 1914
and grew up on a small farm in South Haven, Michigan. He
received his undergraduate degree in chemistry from the
University of Michigan and, after earning a master’s degree
at the University of Chicago, entered the Johns Hopkins
University School of Medicine, receiving his medical degree
in 1941. He completed his surgical residency at Johns
Hopkins and at Massachusetts General Hospital (MGH).
Urist joined the war in 1943 as Chief of Orthopaedics in the
22nd General Hospital Division in England, and the 97th
General Hospital Division in Germany. After resigning from
the military, he became a senior resident at MGH and com-
pleted his training with a fellowship in orthopaedic surgery at
Children’s Hospital in Boston, where he worked on the man-
agement of poliomyelitis. In 1947, he moved to Chicago to
resume his collaboration with Franklin McLean at the
Department of Physiology and Research. His experiments fo-
cused on osteoporosis and hormone regulation of bone ho-
meostasis [2]. In 1948, he joined the faculty of the new
School of Medicine at the University of California at Los
Angeles as an Assistant Professor of Surgery. He was promot-
ed to Associate Professor in 1954 and to Professor of Surgery,
Orthopaedics in 1969. He died at his home on February 4,
2001, in Los Angeles [4].
Dr. Urist’s areas of interest include bone and joint biology,
bone morphogenetic proteins, calcium metabolism, bone
grafts, oestrogens and bone metabolism. He contributed to
the discipline of orthopaedic surgery in many ways but the
main contribution was his interest in basic research [23]. With
grants from a private foundation, he set up the Bone Research
Laboratory in Wilshire.
Bone regeneration was the main concern of Dr. Urist since
his graduation when he read the book by Leriche and Policard
where authors mentioned Bthe juice of stonemaking^ which
generates bone in muscle [2]. The phenomenon of heterotopic
bone formation was best described in experiments performed
by Charles Huggins (1929–1931) on the uroepithelial tissue in
dogs. Huggins was awarded the 1966 Nobel Prize for
Physiology orMedicine for his discovery that hormones could
be used to control the spread of some cancers. This was the
first discovery that cancer could be controlled by chemicals
[14, 15].
In 1965, Dr. Urist showed that new bone formation could
be induced by DBM implanted under the skin or into the
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muscle of animals [29]. With these studies, Dr. Urist
pioneered the concept of substance naturally present in bone,
responsible for the regeneration and bone repair activity. He
called this substance the bone inductive principle BMP, bone
morphogenetic protein, introducing the new term to describe
the nature of this bone inductive factor and initiated a search
for these molecules [30]. He spent the next three decades
isolating and purifying BMP molecules. Throughout the
1970s, pre-clinical research in Dr. Urist’s laboratory demon-
strated the involvement of BMP in the bone formation cascade
of mitosis, chemotaxis, differentiation, callus and bone forma-
tion (endochondral and intramembranous). The advances in
molecular biology in the 1980s and early 1990s allowed the
sequencing and cloning of BMPs. Cloned for the first time in
1988 by a research team at the Genetics Institute led by Dr.
John Wozney, BMP proved to be a member of the TGF-beta
superfamily of cytokines [40]. The first publications on the
clinical use of BMP in non-unions and segmental bone defects
began in the late 1980s by Johnson et al. [16] in tibial defects.
Dr. Urist’s work resulted in the publication of over 400 papers
and the presentations of more than 200 lectures throughout the
world. Availability of rhBMPs permitted the large scale eval-
uation of their efficacy and safety in a large number of animal
models, thus allowing for optimization of both carrier and
dose of BMPs for clinical use [6, 8–11, 13, 17, 19, 21, 22,
24, 27, 38].
Native BMPs were tested in clinical trials under Dr. Urist’s
supervision at the University of California at Los Angeles
(UCLA) where patients with difficult non-unions and bone
defects were successfully treated.
We had an opportunity to personally interact (Fig. 1) and
exchange ideas regarding heterotopic ossification with Dr.
Urist. The first contact was established in 1983 when Prof.
Vukicevic contacted Dr. Urist regarding the discovery of het-
erotopic ossification in the anterior abdominal wall of a ca-
daver found during an anatomical dissection, a case report
published in Plastic and Reconstructive Surgery [39]. The
paper reported on a membranous bone transplant found in
the anterior abdominal wall of an 82-year-old man.
Histological and bone mineral content analyses revealed that
bone graft underwent little bone resorption and induced new
bone formation and that it represented a parietal skull bone
removed following benign brain tumor surgery and implanted
into the abdominal wall for a delayed skull closure [39]. Dr.
Urist kindly replied to the letter, gave useful advice and shared
some of his experience associated with heterotopic ossifica-
tion. In the letter Dr. Urist mentioned that he was workingwith
bone morphogenetic proteins (Fig. 2), which in time became
the main research interest of Professor Vukicevic and his sci-
entific team as well as many international collaborators.
Dr. Vukicevic and Dr. Pecina explored the mechanisms and
function of BMPs in patients with non-unions [3, 7, 20, 21, 26,
31–33, 37], and Dr. Grgurevic made important contributions
to understanding the role of circulating BMPs that led to the
use of BMP6 locally in patients with bone defects [1, 26,
32–34]. With numerous collaborators they published impor-
tant discoveries and organized international BMP conferences
(Figs. 3 and 4).
Dr. Urist was a distinguished leader and his contributions
as a scientist, surgeon, clinician, writer and editor are legend-
ary. He trained and mentored hundreds of young medical res-
idents, fellows and researchers, and his bone laboratory be-
came a centre of scientific and intellectual exchange. Dr. Urist
won numerous academic honours, including two kappa Delta
awards for his work on oestrogen effects on bone and work on
BMPs. The First International Conference on BMP was also
held at Johns Hopkins University in 1994 to honour Dr. Urist.
In 1991, professor Ian Goldie nominated Dr. Urist for the
Nobel Prize in Physiology or Medicine which was based on
his early work on bone physiology and the discovery of bone
formation, BMPs and his clinical research in orthopaedics.
The research area of BMPs has significantly expanded in
the past two decades and covered many areas but has primar-
ily remained in the field of bone regeneration. The foundation
that Dr. Urist set by the discovery of BMPs provided a good
basis for further preclinical research and development of new
bone regeneration products by taking advantage of the basic
characteristics of BMPs as a potent bone-forming agent
in vivo, with the ability of restoring bone loss in postnatal life
by recapitulation of events that are similar to those in the
embryonic development. BMPs are members of the TGF beta
superfamily and have diverse roles in development, repair and
regeneration [34–37]. BMP2 and BMP7 have been most stud-
ied in the context of bone healing [5, 9, 28]. Two therapeutic
concepts have been introduced to the market to overcome
bone non-healing or complicated bone fractures consisting
Fig. 1 Second International BMP Conference Sacramento 1997. From
the left to right: Kuber Sampath, Marshall Urist and Slobodan Vukicevic
Fig. 2 Marshall Urist’s letter to Slobodan Vukicevic. It relates to the




of bovine collagen as a carrier which is soaked with BMP2
(Infuse BoneGraft) or BMP7 (Osigraft) [8, 18, 33]. BMP2 has
received approval for several clinical indications (open tibial
shaft fractures and anterior fusion of the lumbar spine in pa-
tients with degenerative disc disease [DDD]). Due to serious
side effects of BMP2 [12, 25] there is still a need to develop
safer and more effective therapies for bone regeneration. In
order to avoid the occurrence of side effects and limitations
which include ectopic ossification outside the bone compart-
ment, oedema, inflammation, bovine collagen as a BMP car-
rier, and a high product price, new therapeutic concepts are
being developed and tested in a large number of preclinical
animal models. OSTEOGROW is a new bone device
consisting of BMP6 and a biocompatible blood coagulum-
derived carrier currently tested in Phase I/II clinical testing
in patients with high tibial osteotomy (HTO) and distal radius
fracture (DRF) in three European countries. The first safety
report after completion of Phase II in patients with HTO indi-
cate that no serious side effects have been reported [33, 34].
The existence of a link between the founder and those who
learn from him proved to be in accordance with the metaphor:
standing on the shoulders of giants (Latin: nanos gigantum
humeris insidentes) expressing the meaning of Bdiscovering
truth by building on previous discoveries^. The concept has
been traced to the 12th century, attributed to Bernard of
Chartres [11]. The future of BMPs as regulators of almost all
developmental and postnatal events provides a platform for
future discoveries on segmental bone healing and systemic
bone biology [34].
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